Predictable revenues pull PE to specialty pharmacies: 5 deals

Specialty pharmacies with multi-state operations and licenses often supply a range of hard-to-access pharmaceuticals. These vendors also have negotiating leverage with various payers and manufacturers. This scale is attracting private equity, as it helps create durable margins and diverse revenue streams that can offset regulatory and reimbursement risks.

Predictable revenue from refills for chronic and complex conditions paired with the sector’s fragmented nature further add to its appeal.

Starting from the most recent, PE Hub rounded up five deals in specialty pharmacy.

1. Linden Capital Partners acquires ArtesRx from Flexpoint Ford

Flexpoint Ford announced in August that it closed the sale of ArtesRx, a behavioral healthcare pharmacy, to Linden Capital Partners.

Based in Amherst, New York, ArtesRx serves patients with complex medication regimens for mental illness, substance use disorders and intellectual and developmental disabilities.

Flexpoint formed the business in 2023 alongside Dom Meffe, then a senior adviser for the PE firm. It created an in-house M&A engine for the company to pursue add-on acquisitions. Through M&A and organic growth, ArtesRx expanded from three pharmacies in one state to 16 pharmacies in 14 states and Washington, DC. One acquisition was of Parkview Health Services in 2023. Flexpoint also built out the executive leadership team and strengthened the sales infrastructure of the company.

2. New Heritage Capital invests in Carepoint Pharmacy 

Also in August, New Heritage Capital announced an investment in Carepoint Pharmacy.

Carepoint is based in Schaumburg, Illinois, and combines pharmacy dispensing in all 50 states with patient access support services for medications that are difficult to obtain otherwise. It also works with pharmaceutical manufacturers on access and affordability programs to help patients navigate the reimbursement process.

The deal was structured under Heritage’s Private IPO model, which keeps operating control with Carepoint’s existing management while providing capital to support growth.

3. Court Square- and WindRose-backed Soleo Health snaps up Realo Specialty Care Pharmacy

In June, Soleo Health, an independent specialty pharmacy and infusion therapy provider backed by Court Square Capital Partners and WindRose Health Investors, announced that it acquired Realo Specialty Care Pharmacy from Realo Drugs. It also acquired ambulatory infusion center BluHaven Management as part of the transaction.

The deal expands Soleo Health’s footprint in the Mid-Atlantic region, primarily in North Carolina, South Carolina, Virginia and Maryland.

Based in Morrisville, North Carolina, Realo supplies in-home infusion therapy and other specialty care medications from an affiliated network of regional community and extended care sites across 49 states.

Soleo Health is headquartered in Frisco, Texas, and operates 28 specialty pharmacies with national nursing coverage and pharmacy licenses in 50 states. It also has over 30 ambulatory infusion suites and centers. Court Square and WindRose invested in the company in 2025.

4. Frazier acquires Altruix from WindRose

WindRose Health Investors announced in May the sale of Altruix, a behavioral healthcare pharmacy, to Frazier Healthcare Partners.

Operating out of Cockeysville, Maryland, Altruix serves patients with mental illness, substance use disorders and intellectual and developmental disabilities. It also provides high-touch pharmacy services, care co-ordination and access to specialty and limited-distribution drugs at 17 pharmacies across the Mid-Atlantic.

“Over the course of our partnership, the company expanded its geographic footprint, deepened its omnichannel service capabilities, strengthened key pharma and payer partnerships and built a best-in-class leadership team,” said CJ Burnes, partner at WindRose, in a statement.

WindRose invested in the company in 2021 when it was called Terrapin Pharmacy. It also acquired and merged another specialty pharmacy, Ganse Apothecary, with the company in 2022. Terrapin Pharmacy rebranded as Altruix in 2023.

5. Nautic Partners closes investment in SenderraRx

In March, Nautic Partners announced it completed a growth investment in SenderraRx, a specialty pharmacy based in Dallas. The PE firm announced an agreement to invest in the company in December.

Founded in 2010, SenderraRx provides medications for complex and chronic conditions in areas of dermatology, rheumatology and oncology to patients in all 50 states.

SenderraRx’s management team will remain significant investors and continue to lead the company.

As dealmakers seek targets that offer consolidation opportunities and predictable revenues, PE Hub expects to see more deals involving specialty pharmacies in the coming months.